Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 12;28(5):545–553. doi: 10.1111/iju.14505

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2 — LS mean change (standard error) in IC/BPS symptoms and voiding parameters from baseline at each visit in the KRP‐116D and placebo groups with respect to: (a) ICSI; (b) ICPI; (c) NRS for bladder pain; (d) number of micturitions/24 h; (e) voided volume/micturition (mL); and (f) maximum voided volume/micturition (mL). The differences in the primary and secondary efficacy variables for the KRP‐116D and placebo groups were calculated using a mixed model for repeated measures. *P < 0.05, **P < 0.001. KRP‐116D and placebo.

Inline graphic — LS mean change (standard error) in IC/BPS symptoms and voiding parameters from baseline at each visit in the KRP‐116D and placebo groups with respect to: (a) ICSI; (b) ICPI; (c) NRS for bladder pain; (d) number of micturitions/24 h; (e) voided volume/micturition (mL); and (f) maximum voided volume/micturition (mL). The differences in the primary and secondary efficacy variables for the KRP‐116D and placebo groups were calculated using a mixed model for repeated measures. *P < 0.05, **P < 0.001. KRP‐116D and placebo.